<DOC>
	<DOCNO>NCT00163540</DOCNO>
	<brief_summary>The objective study investigate immunogenicity safety third vaccination FSME-IMMUN 0.5 ml give approximately 12 month second vaccination Study 225 . In Study 225 , two vaccination give use rapid immunization schedule 12 Â± 2 day apart .</brief_summary>
	<brief_title>Immunogenicity Safety Study Third Vaccination With FSME-IMMUN 0.5 mL Subjects Previously Vaccinated According Rapid Immunization Schedule ( Follow-up Study 225 )</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Tick-Borne</mesh_term>
	<mesh_term>Formaldehyde</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject : receive 2 vaccination FSMEIMMUN 0.5 ml Study 225 understand nature study , agree provision provide write informed consent clinically healthy ( i.e . physician would reservation vaccinate FSMEIMMUN 0.5 ml outside scope clinical trial ) negative pregnancy test result first medical examination ( female capable bearing child ) agree employ adequate birth control measure duration study ( female capable bearing child ) agree keep Subject Diary Subjects : already administer third TBE vaccination elsewhere since receive two vaccination Study 225 history infection , vaccination , flavivirus since participation Study 225 ( e.g . yellow fever , dengue fever , japanese B encephalitis ) allergic reaction one component vaccine since participation Study 225 suffer disease ( e.g . autoimmune disease , immunodeficiency ) undergo form treatment ( e.g. , systemic corticosteroid ) expect influence immunological function know suspected problem drug alcohol abuse ( &gt; 4 liter wine/week equivalent dos alcoholic beverage ) donate blood plasma within 30 day study entry receive blood transfusion immunoglobulin within 30 day study entry know HIV positive ( HIV test require specifically study ) simultaneously participate another clinical trial include administration investigational product participate clinical study within 6 week prior study start participate another Baxter vaccine study past 6 month ( exception followup study ) For female subject : pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>tick-borne encephalitis</keyword>
</DOC>